乙酰谷酰胺联合依达拉奉治疗脑梗死的效果观察

Effect Observation of Aceglutamide Combined with Edaravone in Treatment of Cerebral Infarction

目的:探讨乙酰谷酰胺联合依达拉奉治疗脑梗死的效果。方法:选取2020年1月-2021年3月谷城县中医医院收治的112例脑梗死患者作为研究对象,随机分为两组,各56例。对照组实施常规治疗,观察组在对照组基础上应用乙酰谷酰胺联合依达拉奉治疗。比较两组治疗效果。结果:治疗后,观察组美国国立卫生院卒中量表评分低于对照组,Barthel指数高于对照组,差异有统计学意义(P<0.05);观察组治疗有效率高于对照组,差异有统计学意义(P<0.05);治疗后,观察组神经肽Y、重组人半乳糖凝集素3及粒细胞-巨噬细胞集落刺激因子水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:乙酰谷酰胺联合依达拉奉治疗脑梗死的效果确切,有效促进了神经功能的修复,且安全性高,值得推广应用。

Objective: To investigate the effect of aceglutamide combined with edaravone in the treatment of cerebral infarction. Methods: From January 2020 to March 2021, 112 patients with cerebral infarction in Gucheng County Hospital of Traditional Chinese Medicine were selected as the study subjects and randomly divided into two groups, with 56 cases in each group. The control group was given conventional treatment, on this basis, the observation group was given aceglutamide combined with edaravone treatment. The treatment effects in two groups were compared. Results: After treatment, the National Institutes of Health Stroke Scale score in the observation group was lower than that in the control group, and the Barthel index was higher than that in the control group, and the difference was statistically significant (P<0.05). The treatment effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05);after treatment, the levels of neuropeptide Y, recombinant human galectin-3 and granulocyte-macrophage colony-stimulating factor in the observation group were all lower than those in the control group, and the difference was statistically significant (P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Aceglutamide combined with edaravone in the treatment of cerebral infarction is effective, effectively promotes the repair of nerve function, and has high safety, which is worthy of popularization and application.